BioLine Rx
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 79
- Market Cap
- $59.2M
- Website
- http://www.biolinerx.com
- Introduction
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumor...
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05293171
- Locations
- 🇺🇸
Celerion, Phoenix, Arizona, United States
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT03246529
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Loyola University Medical Center, Chicago, Illinois, United States
ðŸ‡ðŸ‡ºUniversity of Debrecen, Debrecen, Hungary
A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT03154827
- Locations
- 🇺🇸
Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States
🇺🇸The University of Texas - Md Anderson Cancer Center - Leukemia Center, Houston, Texas, United States
🇨🇿Fakultni Nemocnice Brno / University Hospital Brno Interni Hematologicka A Onkologicka Klinika / Internal Hematology and Oncology Clinic, Brno, Czechia
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT02826486
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center (BIDMAC), Boston, Massachusetts, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇮🇱Sourasky Medical Center, Tel Aviv, Israel
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT02462252
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT02073019
- Locations
- 🇮🇱
Hadassah Clinical Research Center, Jerusalem, Israel
Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01990885
- Locations
- 🇫🇮
FinnMedi Clinical Trial Center, Tampere, Finland
🇫🇮CRST Clinical Research Services, Turku, Finland
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT01838395
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT01833845
- Locations
- 🇫🇷
Hospital St. Joseph, Marseille, France
🇫🇷Cochin Hospital, Paris, France
Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- BioLineRx, Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT01506362
- Locations
- 🇮🇱
Shaare Zedek Medical center, Jerusalem, Israel
🇮🇱Hadassah medical center, Jerusalem, Israel
🇮🇱Soroka Medical Center, Be'er Sheva, Israel